5 Citations (Scopus)

Abstract

Physicians who treat multiple sclerosis (MS) face the challenge of patients exhibiting ongoing disease activity, including exacerbations, loss of functional capabilities, intellectual decline, and radiologic progression, despite being on a disease-modifying agent (DMA). After searching for factors that might at least in part explain these changes-such as nonadherent drug-taking behavior, or the presence of interferon-neutralizing antibodies-some providers may ultimately decide to switch the patient to another DMA. In most circumstances, patients likely derive only partial effects from these agents, even in the absence of compromising factors. Thus, a number of factors must be considered in order to intensify the treatment regimen in response to disease progression. In the context of an inadequate treatment response to a DMA, some clinicians will convert the patient to an alternative therapy, and others will instead use a second agent in combination with the first (the so-called platform agent). In the first of this two-part series, we explored the use of anti-inflammatory CS and ACTH to treat MS exacerbations. Although we underscored the limited availability of evidence-based studies to support specific regimens for this purpose, there is an even greater paucity of data to support the routine use of these agents in order to achieve chronic disease-modifying effects in those who continue to deteriorate clinically, radiographically, or both. Without doubt, a number of factors influence the formulation of combination treatment plan for MS. Nevertheless, we will focus on the rationale and practical schemes that can be considered for using corticosteroids (CS) (and perhaps even ACTH) in an attempt to modify various domains of ongoing disease activity.

Original languageEnglish (US)
Pages (from-to)627-632
Number of pages6
JournalNeurotherapeutics
Volume4
Issue number4
DOIs
StatePublished - Oct 2007

Fingerprint

Multiple Sclerosis
Adrenal Cortex Hormones
Adrenocorticotropic Hormone
Complementary Therapies
Neutralizing Antibodies
Interferons
Disease Progression
Chronic Disease
Anti-Inflammatory Agents
Therapeutics
Physicians
Pharmaceutical Preparations

Keywords

  • ACTH
  • Corticosteroids
  • pulse steroids

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Pharmacology

Cite this

Corticosteroids for Multiple Sclerosis : II. Application for Disease-Modifying Effects. / Shah, Anjali; Eggenberger, Eric; Zivadinov, Robert; Stuve, Olaf; Frohman, Elliot.

In: Neurotherapeutics, Vol. 4, No. 4, 10.2007, p. 627-632.

Research output: Contribution to journalArticle

@article{4ea5f9feb525496aae7e009c3c1739b3,
title = "Corticosteroids for Multiple Sclerosis: II. Application for Disease-Modifying Effects",
abstract = "Physicians who treat multiple sclerosis (MS) face the challenge of patients exhibiting ongoing disease activity, including exacerbations, loss of functional capabilities, intellectual decline, and radiologic progression, despite being on a disease-modifying agent (DMA). After searching for factors that might at least in part explain these changes-such as nonadherent drug-taking behavior, or the presence of interferon-neutralizing antibodies-some providers may ultimately decide to switch the patient to another DMA. In most circumstances, patients likely derive only partial effects from these agents, even in the absence of compromising factors. Thus, a number of factors must be considered in order to intensify the treatment regimen in response to disease progression. In the context of an inadequate treatment response to a DMA, some clinicians will convert the patient to an alternative therapy, and others will instead use a second agent in combination with the first (the so-called platform agent). In the first of this two-part series, we explored the use of anti-inflammatory CS and ACTH to treat MS exacerbations. Although we underscored the limited availability of evidence-based studies to support specific regimens for this purpose, there is an even greater paucity of data to support the routine use of these agents in order to achieve chronic disease-modifying effects in those who continue to deteriorate clinically, radiographically, or both. Without doubt, a number of factors influence the formulation of combination treatment plan for MS. Nevertheless, we will focus on the rationale and practical schemes that can be considered for using corticosteroids (CS) (and perhaps even ACTH) in an attempt to modify various domains of ongoing disease activity.",
keywords = "ACTH, Corticosteroids, pulse steroids",
author = "Anjali Shah and Eric Eggenberger and Robert Zivadinov and Olaf Stuve and Elliot Frohman",
year = "2007",
month = "10",
doi = "10.1016/j.nurt.2007.07.009",
language = "English (US)",
volume = "4",
pages = "627--632",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Corticosteroids for Multiple Sclerosis

T2 - II. Application for Disease-Modifying Effects

AU - Shah, Anjali

AU - Eggenberger, Eric

AU - Zivadinov, Robert

AU - Stuve, Olaf

AU - Frohman, Elliot

PY - 2007/10

Y1 - 2007/10

N2 - Physicians who treat multiple sclerosis (MS) face the challenge of patients exhibiting ongoing disease activity, including exacerbations, loss of functional capabilities, intellectual decline, and radiologic progression, despite being on a disease-modifying agent (DMA). After searching for factors that might at least in part explain these changes-such as nonadherent drug-taking behavior, or the presence of interferon-neutralizing antibodies-some providers may ultimately decide to switch the patient to another DMA. In most circumstances, patients likely derive only partial effects from these agents, even in the absence of compromising factors. Thus, a number of factors must be considered in order to intensify the treatment regimen in response to disease progression. In the context of an inadequate treatment response to a DMA, some clinicians will convert the patient to an alternative therapy, and others will instead use a second agent in combination with the first (the so-called platform agent). In the first of this two-part series, we explored the use of anti-inflammatory CS and ACTH to treat MS exacerbations. Although we underscored the limited availability of evidence-based studies to support specific regimens for this purpose, there is an even greater paucity of data to support the routine use of these agents in order to achieve chronic disease-modifying effects in those who continue to deteriorate clinically, radiographically, or both. Without doubt, a number of factors influence the formulation of combination treatment plan for MS. Nevertheless, we will focus on the rationale and practical schemes that can be considered for using corticosteroids (CS) (and perhaps even ACTH) in an attempt to modify various domains of ongoing disease activity.

AB - Physicians who treat multiple sclerosis (MS) face the challenge of patients exhibiting ongoing disease activity, including exacerbations, loss of functional capabilities, intellectual decline, and radiologic progression, despite being on a disease-modifying agent (DMA). After searching for factors that might at least in part explain these changes-such as nonadherent drug-taking behavior, or the presence of interferon-neutralizing antibodies-some providers may ultimately decide to switch the patient to another DMA. In most circumstances, patients likely derive only partial effects from these agents, even in the absence of compromising factors. Thus, a number of factors must be considered in order to intensify the treatment regimen in response to disease progression. In the context of an inadequate treatment response to a DMA, some clinicians will convert the patient to an alternative therapy, and others will instead use a second agent in combination with the first (the so-called platform agent). In the first of this two-part series, we explored the use of anti-inflammatory CS and ACTH to treat MS exacerbations. Although we underscored the limited availability of evidence-based studies to support specific regimens for this purpose, there is an even greater paucity of data to support the routine use of these agents in order to achieve chronic disease-modifying effects in those who continue to deteriorate clinically, radiographically, or both. Without doubt, a number of factors influence the formulation of combination treatment plan for MS. Nevertheless, we will focus on the rationale and practical schemes that can be considered for using corticosteroids (CS) (and perhaps even ACTH) in an attempt to modify various domains of ongoing disease activity.

KW - ACTH

KW - Corticosteroids

KW - pulse steroids

UR - http://www.scopus.com/inward/record.url?scp=34848898853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848898853&partnerID=8YFLogxK

U2 - 10.1016/j.nurt.2007.07.009

DO - 10.1016/j.nurt.2007.07.009

M3 - Article

C2 - 17920543

AN - SCOPUS:34848898853

VL - 4

SP - 627

EP - 632

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 4

ER -